While a mutation in the BCR-ABL1 kinase domain is known to be one of the major determinants of TKI resistance and a risk for blastic transformation2, additional genetic alterations have been hypothesised to be necessary for the progression to BC. This evidence concerns the gene ABL1 and breast cancer.